NanoCarrier Co., Ltd. (4571) AI Stock Analysis

• Market Cap: ¥10.48B
• Dividend Yield: N/A
• Average Volume (3M): 2.35M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.83
• Revenue Growth: 172.39%
• EPS Growth: 8.27%
• Country: JP
• Employees: 18
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.35
• Shares Outstanding: 75,374,160
• 10 Day Avg. Volume: 484,410
• 30 Day Avg. Volume: 2,345,523
• PEG Ratio: -1.80
• Price to Book (P/B): 3.71
• Price to Sales (P/S): 93.58
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: ¥134.00 ▲(0.00% Upside)

The score is primarily held down by weak financial performance driven by declining revenue, persistent large losses, and continued cash burn. Technical signals are also soft with the stock below key moving averages and negative MACD, while valuation is constrained by negative earnings and no dividend support.

Positive Factors

High Gross Margin

A high gross margin indicates efficient production and pricing strategies, providing a buffer against operational inefficiencies and supporting potential profitability improvements.

Manageable Leverage

Low leverage enhances financial flexibility, allowing the company to navigate through challenging periods without excessive debt burdens, supporting long-term stability.

Improved Cash Burn Rate

An improved cash burn rate suggests better cost management and operational efficiency, which can extend the company's runway and reduce the need for external financing.

Negative Factors

Declining Revenue

Continued revenue decline limits scale and operating leverage, challenging the company's ability to cover fixed costs and invest in growth, impacting long-term viability.

Persistent Large Losses

Ongoing large losses indicate that expenses significantly exceed revenues, which can erode equity and limit the company's ability to invest in future growth opportunities.

Negative Cash Flow

Negative cash flow suggests the company is not generating sufficient cash from operations to sustain itself, increasing reliance on external funding and posing a risk to long-term sustainability.

NanoCarrier Co., Ltd. Business Overview & Revenue Model

Company Description

NANO MRNA Co., Ltd. engages in the research, development, and production of pharmaceuticals using micellar nanoparticles technology. The company develops biopharmaceutical products focused on the medication of cancer and other intractable diseases. It also engages in the research, development, manufacture, and sale of anti-cancer drugs based on micellar nanoparticle technology. The company was founded by Kazunori Kataoka, Teruo Okano, and Ichiro Nakatomi on June 14, 1996 and is headquartered in Tokyo, Japan.

How the Company Makes Money

NanoCarrier Co., Ltd. generates revenue primarily through the development, licensing, and commercialization of its proprietary drug delivery systems. The company collaborates with pharmaceutical companies to co-develop drugs using its nanotechnology platforms, earning revenues from licensing fees, milestone payments, and royalties on sales of co-developed products. Additionally, NanoCarrier may receive funding from government grants or private investments to support its research and development activities. Strategic partnerships and collaborations with other biotech and pharmaceutical companies also play a significant role in enhancing its market reach and financial performance.

NanoCarrier Co., Ltd. Financial Statement Overview

Summary

Income statement and cash flow are very weak: multi-year declining revenue, very large operating/net losses, and ongoing negative operating cash flow/free cash flow indicate continued cash burn. The balance sheet is moderately supportive with manageable leverage and reduced debt, but recurring losses are eroding equity and keep returns deeply negative.

Income Statement

Revenue has been shrinking for several years (down again in FY2025), which is a clear negative for scale and operating leverage. While gross margin remains very high (~72% in FY2025), the company continues to post very large operating and net losses (FY2025 net margin roughly -770%), indicating that operating expenses and R&D spend are far above the current revenue base. Losses have improved versus the worst year (FY2022–FY2023), but profitability remains structurally weak and visibility to breakeven appears limited based on the provided trend.

Balance Sheet

Leverage looks manageable with debt-to-equity around 0.20 in FY2025 and total debt reduced materially versus FY2024, which supports financial flexibility. However, equity has been declining over time, consistent with repeated net losses, and returns on equity remain deeply negative (about -30% in FY2025). Overall, the balance sheet is not highly levered, but ongoing losses are eroding the capital base and remain the key risk.

Cash Flow

Cash generation is weak: operating cash flow is negative across all reported years and was still meaningfully negative in FY2025, implying continued cash burn to fund operations. Free cash flow has been negative historically (notably FY2022–FY2024), and the business has not demonstrated a sustained ability to self-fund, increasing reliance on financing or existing liquidity. The pace of burn has improved from earlier years, but remains a material overhang.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	116.10M	108.52M	135.51M	202.19M	264.03M	313.26M
Gross Profit	84.46M	78.17M	110.96M	159.60M	222.74M	274.89M
EBITDA	-776.70M	-832.57M	-863.00M	-1.25B	-2.06B	-1.30B
Net Income	-879.96M	-835.38M	-780.00M	-1.31B	-1.88B	-2.84B
Balance Sheet
Total Assets	3.93B	4.00B	5.07B	5.78B	7.14B	7.82B
Cash, Cash Equivalents and Short-Term Investments	3.40B	3.51B	4.28B	4.44B	5.95B	6.40B
Total Debt	540.24M	540.24M	1.11B	1.11B	1.15B	0.00
Total Liabilities	1.28B	1.26B	1.65B	1.53B	1.57B	321.00M
Stockholders Equity	2.66B	2.74B	3.42B	4.25B	5.57B	7.50B
Cash Flow
Free Cash Flow	0.00	0.00	-585.08M	-1.09B	-1.76B	-1.25B
Operating Cash Flow	0.00	-401.62M	-585.08M	-1.09B	-1.75B	-1.25B
Investing Cash Flow	0.00	587.53M	793.01M	1.21B	-244.13M	-871.69M
Financing Cash Flow	0.00	-568.77M	3.73M	32.20M	1.15B	-11.46M

NanoCarrier Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 134.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4571, the sentiment is Negative. The current price of 134 is below the 20-day moving average (MA) of 143.00, below the 50-day MA of 143.70, and below the 200-day MA of 144.22, indicating a bearish trend. The MACD of -1.61 indicates Positive momentum. The RSI at 41.74 is Neutral, neither overbought nor oversold. The STOCH value of 27.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4571.

NanoCarrier Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4584	59 Neutral	¥12.05B	38.22	―	―	83.60%	―
4594	53 Neutral	¥9.36B	-5.89	―	―	1221.43%	30.54%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4588	50 Neutral	¥49.97B	-21.62	―	―	-9.04%	13.09%
2370	46 Neutral	¥7.97B	-5.83	―	―	5.44%	-2.17%
4583	45 Neutral	¥7.85B	-8.63	―	―	25.28%	39.15%
4571	40 Underperform	¥10.48B	-13.00	-26.70%	―	172.39%	8.27%